argenx shares rocket on news of $1.6 billion cusatuzumab deal

4 December 2018
2019_biotech_test_vial_discovery_big

Belgo-Dutch biotech argenx (Euronext Brussels: ARGX) yesterday announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110), adding to its lucrative deal in the summer with AbbVie (NYSE: ABBV), with the news sending its share leaping 13% to 10.90 euros by close of trading on Monday.

Cusatuzumab, a highly differentiated anti-CD70 SIMPLE AntibodyÔ, has been licensed to Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ).

Cusatuzumab is currently in development in a Phase I/II combination study with Vidaza (azacitidine) for newly-diagnosed, elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who are unfit for chemotherapy. Data announced from the Phase I/II study will be presented during a workshop being held in conjunction with the 60th American Society of Hematology Annual Meeting and Exposition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology